Condition (MeSH)
Choriocarcinoma
ClinicalTrials.gov lists 13 trials for Choriocarcinoma or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
13 of the 13 trials are tagged with Choriocarcinoma itself; the rest are tagged with a narrower condition beneath it.
When did Choriocarcinoma trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2016 | 1 |
| 2015 | 2 |
| 2012 | 1 |
| 2010 | 1 |
| 2007 | 1 |
| 2006 | 2 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Choriocarcinoma trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 2 |
| Not applicable | 1 |
| Observational | 4 |
How many Choriocarcinoma trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 2 |
| Completed | 4 |
| Terminated | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Choriocarcinoma trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Children's Oncology Group | 2 |
| Tracon Pharmaceuticals Inc. | 2 |
| AstraZeneca | 1 |
| Eli Lilly and Company | 1 |
| GOG Foundation | 1 |
Which drugs are being tested for Choriocarcinoma? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Dactinomycin | 2 |
| Calcium Leucovorin | 2 |
| TRC105 | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ifosfamid | 2 |
| or carboplatin | 2 |
| Etoposid | 2 |
| HD- Methotrexate (MTX) | 2 |
| Bevacizumab 1 | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Choriocarcinoma trials report? (7)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Appendicitis | 1 | 1 |
| Headache | 1 | 1 |
| Infusion Related Reaction | 1 | 1 |
| Malaise | 1 | 1 |
| Migraine | 1 | 1 |
Showing 5 of 7 adverse events.
Which publications cover Choriocarcinoma? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Trophoblastic disease. | Minnesota medicine | 1967 | Yes |
| Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. | American journal of obstetrics and gynecology | 2010 | No |
| Human leucocyte antigen (HLA) expression of primary trophoblast cells and placental cell lines, determined using single antigen beads to characterize allotype specificities of anti-HLA antibodies. | Immunology | 2009 | No |
| Management and outcome of healthy women with a persistently elevated beta-hCG. | Gynecologic oncology | 2007 | No |
| Epigenetic regulation of human trophoblastic cell migration and invasion. | Endocrinology | 2006 | No |
Showing 5 of 8 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.